Results 51 to 60 of about 166,368 (358)

Optimizing survival outcomes with post-remission therapy in acute myeloid leukemia. [PDF]

, 2019
Optimization of post-remission therapies to maintain complete remission and prevent relapse is a major challenge in treating patients with acute myeloid leukemia (AML).
Chan, Steven M, Daver, Naval G, Jonas, Brian A, Medeiros, Bruno C, Pollyea, Daniel A   +4 more
core   +1 more source

Inhibition of CDK9 enhances AML cell death induced by combined venetoclax and azacitidine

Molecular Oncology, EarlyView.
The CDK9 inhibitor AZD4573 downregulates c‐MYC and MCL‐1 to induce death of cytarabine (AraC)‐resistant AML cells. This enhances VEN + AZA‐induced cell death significantly more than any combination of two of the three drugs in AraC‐resistant AML cells.
Shuangshuang Wu, Jianlei Zhao, Aaban Asfar Azmi, Avanti Gupte, Jenna Thibodeau, Shuang Liu, Jinli Yang, Guan Wang, Holly Edwards, Lisa A. Polin, Juiwanna Kushner, Sijana H. Dzinic, Kathryn White, Julie Boerner, Maik Hüttemann, Jay Yang, Yue Wang, Jeffrey W. Taub, Yubin Ge   +18 more
wiley   +1 more source

CD4+CD25+FOXP3+ T regulatory cells reconstitute and accumulate in the bone marrow of patients with multiple myeloma following allogeneic stem cell transplantation

Haematologica, 2008
Background Very little is known about the number and function of immunosuppressive CD4+CD25+FOXP3+ T regulatory cells (Treg) in the human bone marrow and it is unclear whether bone marrow-residing Treg are capable of regenerating following allogeneic ...
Djordje Atanackovic, Yanran Cao, Tim Luetkens, Jens Panse, Christiane Faltz, Julia Arfsten, Katrin Bartels, Christine Wolschke, Thomas Eiermann, Axel R. Zander, Boris Fehse, Carsten Bokemeyer, Nicolaus Kroger   +12 more
doaj   +1 more source

Costs of allogeneic hematopoietic stem cell transplantation

Biology of Blood and Marrow Transplantation, 2006
This study aims to determine the total costs after allogeneic hematopoietic stem cell transplantation (ASCT) and factors associated with increases or decreases in costs.We collected all in- and outpatient costs during 5 years in 93 patients who had undergone ASCT in 1998 and 1999 at our unit.
Svahn, B.-M.B.M.S., Alvin, O.O.A., Ringden, O.O.R., Gardulf, A.A.G., Remberger, M.M.R.   +4 more
openaire   +2 more sources

Outcome after allogeneic stem cell transplantation with haploidentical versus HLA-matched donors in patients with higher-risk MDS [PDF]

, 2023
Claire Michel, Marie Robin, Stéphane Morisset, Didier Blaise, Johan Maertens, Patrice Chevalier, Cristina Castilla‐Llorente, Édouard Forcade, Patrice Céballos, Ibrahim Yakoub‐Agha, Xavier Poiré, Martin Carré, Jacques‐Olivier Bay, Yves Béguin, Michaël Loschi, Anne Huynh, Gaëlle Guillerm, Sylvie François, Jean-Baptiste Méar, Rémy Duléry, Felipe Suárez, Karin Bilger, Jérôme Cornillon, Yves Chalandon, Natacha Maillard, Hélène Labussière‐Wallet, A Charbonnier, Pascal Turlure, Ana Berceanu, Sylvain Chantepie, Sébastien Maury, Ali Bazarbachi, Anne‐Lise Ménard, Stéphanie Nguyen‐Quoc, Marie‐Thérèse Rubio, Maud D’Aveni   +35 more
openalex   +1 more source

An injectable bone marrow-like scaffold enhances T cell immunity after hematopoietic stem cell transplantation. [PDF]

, 2019
Allogeneic hematopoietic stem cell transplantation (HSCT) is a curative treatment for multiple disorders, but deficiency and dysregulation of T cells limit its utility.
Deruaz, Maud, Kerr, Matthew D, Mao, Angelo S, Mooney, David J, Raimondo, Theresa M, Scadden, David T, Shah, Nisarg J, Sharda, Azeem, Shih, Ting-Yu, Tager, Andrew M, Vrbanac, Vladimir D, Weaver, James C   +11 more
core   +1 more source

Class IIa HDACs forced degradation allows resensitization of oxaliplatin‐resistant FBXW7‐mutated colorectal cancer

Molecular Oncology, EarlyView.
HDAC4 is degraded by the E3 ligase FBXW7. In colorectal cancer, FBXW7 mutations prevent HDAC4 degradation, leading to oxaliplatin resistance. Forced degradation of HDAC4 using a PROTAC compound restores drug sensitivity by resetting the super‐enhancer landscape, reprogramming the epigenetic state of FBXW7‐mutated cells to resemble oxaliplatin ...
Vanessa Tolotto, Nicolò Gualandi, Ylenia Cortolezzis, Raffaella Picco, Monica Colitti, Francesca D'Este, Mariachiara Gani, Wayne W. Hancock, Giovanni Terrosu, Cristina Degrassi, Francesca Agostini, Claudio Brancolini, Luigi E. Xodo, Eros Di Giorgio   +13 more
wiley   +1 more source

Therapeutic choices in patients with Ph-Positive chronic myelogenous leukemia in Mexico in the era of tyrosine kinase inhibitors: stem cell transplantation or tyrosine kinase inhibitors? Fifteen years later

Revista de Investigación Clínica
Background: Chronic myelogenous leukemia is a neoplastic proliferation of the granulocytic series. In Mexico, chronic myelogenous leukemia accounts for approximately 10% of all leukemias.
Max Robles-Nasta, Daniela Sánchez-Bonilla, Moises M. Gallardo-Pérez, Edgar J. Hernández-Flores, Merittzel A. Montes-Robles, María de L. Pastelín-Martínez, Juan C. Olivares-Gazca, Guillermo J. Ruiz-Delgado, Guillermo J. Ruiz-Argüelles   +8 more
doaj   +1 more source

Strength through diversity: how cancers thrive when clones cooperate

Molecular Oncology, EarlyView.
Intratumor heterogeneity can offer direct benefits to the tumor through cooperation between different clones. In this review, Kuiken et al. discuss existing evidence for clonal cooperativity to identify overarching principles, and highlight how novel technological developments could address remaining open questions.
Marije C. Kuiken, Maartje Witsen, Emile E. Voest, Krijn K. Dijkstra   +3 more
wiley   +1 more source

Analysis of the results of allogeneic hematopoietic stem cell transplantation depending on HLA matching of the unrelated donor / recipient pair

Онкогематология, 2015
HLA matching of the donor / recipient pair is a major factor associated with the outcome of allogeneic stem cell transplantation. In the presentstudy we analyzed the risk of severe acute graft-versus-host disease, graft failure, 2.year overall survival ...
Ye. V. Kuzmich, A. I. Alyanskiy, N. Ye. Ivanova, A. A. Vitrischak, M. D. Vladovskaya, Ye. V. Morozova, S. N. Bondarenko, Ye. V. Semenova, L. S. Zubarovskaya, B. V. Afanasyev   +9 more
doaj   +3 more sources